# OnCo record nct05456685 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05456685/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05456685", "NCT05456685" ;
  schema:name "Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ov"@en ;
  schema:description "A phase 2 trial of Mirvetuximab soravtansine, Carboplatin in ovarian cancer, run by AbbVie, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05456685/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05456685> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2022-09-28" ;
  onco:cancers <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/platinum-sensitive-ovarian-cancer/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/platinum/> ;
  onco:drugs <https://onco.cc/drugs/mirvetuximab-soravtansine/>, <https://onco.cc/drugs/carboplatin/> ;
  onco:companies <https://onco.cc/companies/abbvie/> .